Navigation Links
TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Date:6/23/2008

LA JOLLA, Calif., June 23 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezampanel given subcutaneously for treatment of acute migraine at the 50th Annual Scientific Meeting of the American Headache Society in Boston on Saturday, June 28th at 2:00pm, Eastern.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda C
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
2. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
3. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
4. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. TorreyPines Therapeutics Reports Third Quarter 2007 Results
6. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
8. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
9. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
10. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
11. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... As part of its 2015 growth plan ... and technical service business units, Whitehouse Laboratories is pleased to announce that ... adjacent to the Container Center of Excellence and will be strictly dedicated to basic USP ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... modern world, largely due to properties that render the ... One of their most useful qualities, however - the ... stress - is also one of the most puzzling., ... to change shape to absorb energy rather than breaking ...
... November 27 Arpida,announced today that it is refocusing all ... says this is to be seen as a,consequence of the ... board on 20 November 2008 regarding the,approval of Iclaprim in ... the context of the FDA advisory board,s recommendation the Arpida,board ...
... market and business intelligence company, the biofuel market is estimated at ... of approximately 85% bioethanol and 15% biodiesel. Bioethanol is produced and ... Europe is the world leader in biodiesel production and this fuel ... ...
Cached Biology Technology:Fast molecular rearrangements hold key to plastic’s toughness 2Fast molecular rearrangements hold key to plastic’s toughness 3Arpida to Restructure and Focus on Key Projects 2CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 2CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 3CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 4
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
(Date:7/31/2015)... 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT ... method to advance crypto-currencies such as Bitcoin into the ... uniform way to manage all payments.  ...
(Date:7/30/2015)... 2015 Cellecta, Inc., a U.S.-based provider ... and biomarker discovery, announced the release of its ... all human protein coding genes. CRISPR technology enables ... gene,s function. Cellecta,s new Human Whole Genome CRISPR ... so that researchers can investigate in a single ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... gold purify the air when they are lit up ... experts have discovered. Associate Professor Zhu Huai Yong, ... that glaziers in medieval forges were the first nanotechnologists ... Professor Zhu said numerous church windows across ...
... of the drugs given to many men during their fight ... grow, researchers have found. The findings were published online this ... of the National Academy of Sciences . The results ... decades. Hormone therapy, a common treatment for men with advanced ...
... (MRI) isn,t just for capturing detailed images of the ... developed by Carnegie Mellon University scientist Eric Ahrens, MRI ... cell populations of interest in the living body. ... as immune cells, will greatly aid the study and ...
Cached Biology News:Air-purifying church windows early nanotechnology 2Why a common treatment for prostate cancer ultimately fails 2Why a common treatment for prostate cancer ultimately fails 3Why a common treatment for prostate cancer ultimately fails 4Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 2Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body 3
Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
PEG 8000, Molecular Biology Grade...
... (HDAC) Antibody Sampler Kit Kit Includes: ... #2062, 40 ul Histone Deacetylase 3 (HDAC3) ... 4 (HDAC4) Antibody, Catalog #2072, 40 ul ... 40 ul Histone Deacetylase 6 (HDAC6) Antibody, ...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: